PC3 is a cell line characteristic of prostatic small cell carcinoma
Tóm tắt
The majority of the prostatic cancers are adenocarcinomas characterized by glandular formation and the expression of luminal differentiation markers androgen receptor (AR) and prostate‐specific antigen (PSA). Most adenocarcinomas are indolent and androgen‐dependent. Hormonal therapy that inhibits AR signaling produces symptomatic relief in patients with advanced and metastatic adenocarcinomas. Prostatic small cell neuroendocrine carcinoma (SCNC) is a variant form of prostate cancer (PC). In contrast to adenocarcinoma, the tumor cells of SCNC do not form glands and are negative for AR and PSA. SCNC is extremely aggressive and does not respond to hormonal therapy. The purpose of this study was to compare the important and relevant features of two most commonly used PC cell lines, LNCaP and PC3, with prostatic adenocarcinoma and SCNC.
Xenograft tumors of LNCaP and PC3 were prepared and compared with human prostatic adenocarcinoma and SCNC for the expression of key signaling molecules by immunohistochemistry and Western blot analysis.
LNCaP cells express AR and PSA and their growth is inhibited by androgen withdrawal, similar to human prostatic adenocarcinoma. PC3 cells do not express AR and PSA and their proliferation is independent of androgen, similar to SCNC. Adenocarcinoma cells and LNCaP cells are negative for neuroendocrine markers and stem cell‐associated marker CD44 while SCNC and PC3 cells are positive. LNCaP cells have identical cytokeratin profiles to adenocarcinoma while PC3 cells have cytokeratin profiles similar to SCNC.
LNCaP cells share common features with adenocarcinoma while PC3 cells are characteristic of SCNC. Prostate 71:1668–1679, 2011. © 2011 Wiley‐Liss, Inc.
Từ khóa
Tài liệu tham khảo
Cooperberg MR, 2004, Prostate cancer 2004: Insights from national disease registries, Oncology (Williston Park), 18, 1239
Sun Y, 2009, Neuroendocrine differentiation in prostate cancer, Am J Transl Res, 1, 148
Huang J, 2007, Function and molecular mechanisms of neuroendocrine cells in prostate cancer, Anal Quant Cytol Histol, 29, 128
Bonkhoff H, 2001, Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status, Ann Oncol, 12, S141, 10.1093/annonc/12.suppl_2.S141
WagnerD HuangJ.Small cell carcinoma of the prostate.eMedicine from WebMD.http://emedicine.medscape.com/article/1611899‐overview.2009.
Horoszewicz JS, 1980, The LNCaP cell line—A new model for studies on human prostatic carcinoma, Prog Clin Biol Res, 37, 115
Horoszewicz JS, 1983, LNCaP model of human prostatic carcinoma, Cancer Res, 43, 1809
Kaighn ME, 1979, Establishment and characterization of a human prostatic carcinoma cell line (PC‐3), Invest Urol, 17, 16
Yang Y, 1997, Differential expression of cytokeratin mRNA and protein in normal prostate, prostatic intraepithelial neoplasia, and invasive carcinoma, Am J Pathol, 150, 693
Pertschuk LP, 1995, Immunostaining for prostate cancer androgen receptor in paraffin identifies a subset of men with a poor prognosis, Lab Invest, 73, 302